IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Currently Amended) A camptothecin analog having the structure:







where

X and Y are each independently ~~$NO_2$, $NH_2$, H, F, Cl, Br, I, COOH, OH, O-$C_{1-6}$-alkyl,~~ SH, S-$C_{1-6}$ alkyl, ~~CN,~~ NH-$C_{1-6}$ alkyl, ~~N($C_{1-6}$-alkyl)$_2$,~~ CHO, ~~$C_{1-8}$-alkyl,~~ $N_3$,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-($C_{1-6}$ alkyl)$_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3, or

-$CH_2$-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, $OSO_2R^1$, $OSO_2CF_3$, $OSO_2C_4F_9$, $C_{1-6}$ alkyl-C(=O)-, $C_{4-18}$ aryl-C(=O)-, $C_{1-6}$ alkyl-$SO_2$-, perfluoro $C_{1-6}$ alkyl-$SO_2$- or $C_{4-18}$ aryl-$SO_2$-, (where each $R^1$ independently is $C_{1-6}$ alkyl, $C_{4-18}$ aryl or $C_{4-18}$ Ar$C_{1-6}$ alkyl); ~~or~~

~~-$CH_2NR^2R^3$, where (a) $R^2$ and $R^3$ are, independently, hydrogen, $C_{1-6}$ alkyl, $C_{3-7}$ cycloalkyl, $C_{3-7}$ cycloalkyl $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, hydroxy $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy $C_{1-6}$ COR$^4$ where $R^4$ is hydrogen, $C_{1-6}$ alkyl, perhalo $C_{1-6}$ alkyl, $C_{3-7}$ cycloalkyl, $C_{3-7}$ cycloalkyl $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, hydroxyl $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, or $C_{1-6}$ alkoxy $C_{1-6}$ alkyl, or (b) $R^2$ and~~

~~$R^3$ taken together with the nitrogen atom to which they are attached form a saturated 3-7 membered heterocyclic ring which may contain a O, S or $NR^5$ group, where $R^5$ is hydrogen, $C_{1-6}$ alkyl, perhalo $C_{1-6}$ alkyl, aryl, aryl substituted with one or more groups selected from the group consisting of $C_{1-6}$ alkyl, halogen, nitro, amino, $C_{1-6}$ alkylamino, perhalo $C_{1-6}$ alkyl, hydroxyl $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkoxy $C_{1-6}$ alkyl and $-COR^6$ where $R^6$ is hydrogen, $C_{1-6}$ alkyl perhalo $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, aryl, and aryl substituted with one or more $C_{1-6}$ alkyl, perhalo $C_{1-6}$ alkyl, hydroxyl $C_{1-6}$ alkyl, or $C_{1-6}$ alkoxy $C_{1-6}$ alkyl groups;~~

$R^7$ is ~~H, or $C(O)(CH_2)_m NR^8R^9$, where m is an integer of 1-6 or $-C(O)CHR^{10}NR^8R^9$, where $R^{10}$ is the side chain of one of the naturally occurring α-amino acids, $R^8$ and $R^9$ are, independently, hydrogen, $C_{1-8}$ alkyl or $-C(O)CHR^{11}NR^{12}R^{13}$ where $R^{11}$ is the side chain of one of the naturally occurring α-amino acids and $R^{12}$ and $R^{13}$ are each independently hydrogen or $C_{1-8}$ alkyl~~;

~~W is independently H or F,~~

$R^{13}$ and $R^{14}$ are each H or combine to form a double bond;

and

n is an integer of 1 or 2,

and salts thereof.

Claim 2. (Original) The camptothecin analog of claim 1, wherein n is 1.

Claim 3. (Original) The camptothecin analog of claim 1, wherein Y is $-CH_2$-L.

Claim 4. (Original) The camptothecin analog of claim 1, wherein L is selected from the group consisting of Cl, Br and I.

Claim 5. (Cancelled)

Claim 6. (Original) The camptothecin analog of claim 1, which is selected from the group consisting of R isomers, S isomers and mixtures thereof.

Claim 7. (Original) The camptothecin analog of claim 6, wherein the analog is the S isomer.

Claim 8. (Original) The camptothecin analog of claim 6, wherein the analog is the R isomer.

Claim 9. (Original) The camptothecin analog of claim 6, wherein the analog is an S rich mixture of S and R isomers.

Claim 10. (Original) The camptothecin analog of claim 6, wherein the analog is a R rich mixture of S and R isomers.

Claim 11. (Original) The camptothecin analog of claim 6, wherein the analog is a racemic mixture of R and S isomers.

Claim 12. (Original) A method of treating leukemia or solid tumors comprising administering to a patient in need thereof, the camptothecin analog of claim 1.

Claim 13. (Original) A pharmaceutical composition comprising the camptothecin analog of claim 1.

Claim 14. (Original) A method for inhibiting the enzyme topoisomerase I, comprising contacting a DNA-topoisomerase I complex with the camptothecin analog of claim 1.

Claim 15. (Currently Amended) A method of preparing the camptothecin analog according to claim 1 comprising:

condensing a compound of formula IV or V




(IV)




(V)

where X, Y, W and n are as defined in claim 1,

with a tricyclic ketone of formula III




(III)

where $R^{13}$ and $R^{14}$ are as defined in claim 1

to form the camptothecin analog of claim 1.

Claim 16. (New) A camptothecin analog having the structure:




(II)

where

X is $NO_2$, $NH_2$, H, F, Cl, Br, I, COOH, OH, O-$C_{1-6}$ alkyl, SH, S-$C_{1-6}$ alkyl, CN, NH-$C_{1-6}$ alkyl, N($C_{1-6}$ alkyl)$_2$, CHO, $C_{1-8}$ alkyl, $N_3$,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-($C_{1-6}$ alkyl)$_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3,

-$CH_2$-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, $OSO_2R^1$, $OSO_2CF_3$, $OSO_2C_4F_9$, $C_{1-6}$ alkyl-C(=O)-, $C_{4-18}$ aryl-C(=O)-, $C_{1-6}$ alkyl-$SO_2$-, perfluoro $C_{1-6}$ alkyl-$SO_2$- or $C_{4-18}$ aryl-$SO_2$-, (where each $R^1$ independently is $C_{1-6}$ alkyl, $C_{4-18}$ aryl or $C_{4-18}$ Ar$C_{1-6}$ alkyl); or

-$CH_2NR^2R^3$, where (a) $R^2$ and $R^3$ are, independently, hydrogen, $C_{1-6}$ alkyl, $C_{3-7}$ cycloalkyl, $C_{3-7}$ cycloalkyl $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, hydroxy $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy $C_{1-6}$ $COR^4$

where $R^4$ is hydrogen, $C_{1-6}$ alkyl, perhalo $C_{1-6}$ alkyl, $C_{3-7}$ cycloalkyl, $C_{3-7}$ cycloalkyl-$C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, hydroxyl-$C_{1-6}$ alkyl, $C_{1-6}$-alkoxy, or $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl;

Y is SH, S-$C_{1-6}$ alkyl, NH-$C_{1-6}$ alkyl, -CHO, $N_3$,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-$(C_{1-6}$ alkyl$)_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3, or

-$CH_2$-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, $OSO_2R^1$, $OSO_2CF_3$, $OSO_2C_4F_9$, $C_{1-6}$ alkyl-C(=O)-, $C_{4-18}$ aryl-C(=O)-, $C_{1-6}$ alkyl-$SO_2$-, perfluoro $C_{1-6}$ alkyl-$SO_2$- or $C_{4-18}$ aryl-$SO_2$-, (where each $R^1$ independently is $C_{1-6}$ alkyl, $C_{4-18}$ aryl or $C_{4-18}$ Ar$C_{1-6}$ alkyl);

$R^7$ is H;

$R^{13}$ and $R^{14}$ are each H or combine to form a double bond;

and

n is an integer of 1 or 2,

and salts thereof.

Claim 17. (New) A method of treating leukemia or solid tumors comprising administering to a patient in need thereof, the camptothecin analog of claim 16.

Claim 18. (New) A pharmaceutical composition comprising the camptothecin analog of claim 16.

Claim 19. (New) A method for inhibiting the enzyme topoisomerase I, comprising contacting a DNA-topoisomerase I complex with the camptothecin analog of claim 16.

Claim 20. (New) A method of preparing the camptothecin analog according to claim 16 comprising:

condensing a compound of formula IV or V




( IV )




( V )

where X, Y, W and n are as defined in claim 16,

with a tricyclic ketone of formula III




( III )

where $R^{13}$ and $R^{14}$ are as defined in claim 16

to form the camptothecin analog of claim 16.